Mixing Technology: Linear Scalability And Mixing Precision For Nanoparticle Formulation
Nanoparticle-based drug delivery systems—such as lipid nanoparticles (LNPs), polymeric nanoparticles, and hybrid carriers—require high precision in formulation and reproducibility across scales. Variability in particle size, polydispersity, or encapsulation efficiency can directly affect drug performance, stability, and regulatory compliance.
DIANT Pharma has developed a mixing technology intended to enable precise control over nanoparticle formation while maintaining linearly scalable performance from early-stage R&D to full commercial production. The platform design focuses on addressing two recurring concerns in pharmaceutical manufacturing: (1) scale-up consistency and (2) batch-to-batch reproducibility.
1. Linear Scalability Across Development Stages
A commonly reported challenge in nanoparticle formulation is the discrepancy between mixing conditions at small (R&D or preclinical) scale and those used at manufacturing scale. Many systems exhibit non-linear scale-up behavior, requiring re-optimization of flow rates, residence times, or shear forces during process translation. This is particularly problematic in formulations where nanoparticle characteristics are highly sensitive to mixing kinetics.
DIANT Pharma’s system is designed to support linear scalability, whereby key mixing parameters—such as flow rate per channel, Reynolds number, and residence time—are preserved across differently sized systems. The system geometry and flow path design remain consistent, and the larger-scale units can replicate the same fluid dynamics achieved in smaller-scale versions.
As a result, formulations developed at bench scale using DIANT’s R&D unit can, in principle, be transferred to pilot or production-scale equipment without fundamental changes to the mixing regime. This facilitates comparability of material produced at different stages of development and may reduce the need for bridging studies, depending on regulatory requirements.
2. Mixing Precision and Control Over Nanoparticle Attributes
In nanoparticle manufacturing, the mixing step is frequently the most sensitive unit operation, particularly for self-assembly-based systems like LNPs. Parameters such as:
- Particle size and polydispersity index (PDI),
- Encapsulation efficiency,
- Drug loading,
- and surface characteristics
are often governed by the dynamics of mixing between solvent and antisolvent streams. Poorly controlled mixing can result in bimodal distributions, batch failure, or suboptimal product quality.
The DIANT mixing system incorporates precision-machined, fixed mixing elements designed to create consistent and well-characterized mixing conditions. These elements are not subject to physical wear over typical operational lifetimes, and they provide a defined shear and turbulence profile to promote uniform mixing across the cross-section of the flow path.
3. Comparison to Injection-Molded Microfluidic Systems
Single-use microfluidic systems—widely adopted in early-stage nanoparticle research— are often manufactured using plastic injection molding. While effective at small scale and for prototyping, these systems introduce specific concerns for GMP or commercial applications:
- Tool degradation: Over time, the mold used for plastic component production wears down, particularly at microscale geometries. This can lead to inconsistencies in the channel widths, depths, or surface finishes between production lots.
- Dimensional drift: Even minor deviations in channel geometry can result in altered flow rates or shear conditions, leading to changes in nanoparticle properties.
- Limited process feedback: Most single-use systems offer limited opportunities for real-time monitoring or integration with process analytical technology (PAT).
In contrast, DIANT’s mixing units use durable, non-disposable materials with high dimensional stability. This approach is intended to minimize variability over repeated use, providing a more stable baseline for both development and manufacturing. These systems are also better suited to integration with real-time monitoring tools, such as inline particle size analyzers or UV-Vis detectors, which are increasingly required in regulated manufacturing environments.
4. Design and Operational Considerations
Key technical characteristics of DIANT’s mixing systems include:
- Consistent shear and residence time profiles: The internal design supports a reproducible fluidic environment, critical for nanoparticle assembly.
- Wide range of throughput: Systems are available to support volumes ranging from under 1 mL to 100+ liters per hour, depending on the configuration.
- Modular design: Systems can be configured with different input/output paths and integrated into existing upstream or downstream workflows.
- Compatibility with various formulation types: The technology has been used in contexts involving LNPs, polymers, emulsions, and other nanoscale formulations.
The system architecture is also intended to support future automation and scale-up strategies, including closed-loop control, automated cleaning (if applicable), and continuous manufacturing approaches.
5. Implications for Regulatory Strategy and Quality Control
From a regulatory standpoint, reproducibility of critical process parameters (CPPs) is essential for ensuring product quality and batch release. Variability introduced by inconsistencies in mixing hardware, particularly at commercial scale, can complicate both process validation and ongoing manufacturing.
DIANT’s mixing systems are designed with consistent geometry and manufacturing tolerances, reducing one source of process variability. In applications where control of nanoparticle characteristics is required by the product specification (e.g., LNP-based vaccines, siRNA therapeutics, or nanocarrier-based injectables), such control over the mixing step may contribute to a more robust control strategy.
Batch records generated using DIANT’s systems can include defined flow rates, pressure profiles, and temperature controls, providing traceability for both development and GMP use cases. For teams considering technology transfer or CDMO engagement, use of a common mixing platform across development sites may reduce variability during tech transfer.
DIANT Pharma’s mixing technology provides a platform for scale-consistent, precise mixing control applicable to nanoparticle-based drug delivery systems. The system design addresses key technical challenges associated with scale-up and batch reproducibility, offering a mechanically stable alternative to disposable microfluidic approaches.
By preserving fluid dynamics across scales and minimizing mechanical variability, the system architecture supports process development from early-stage formulation through to commercial manufacturing without requiring fundamental changes to mixing behavior. These attributes are relevant to developers seeking to reduce risk in scale-up, improve control over particle characteristics, and meet evolving regulatory expectations for precision medicine and complex injectable products.